news Scientists explore CA2 neuron mitochondria for memory loss targets 10 November 2021 | By Anna Begley (Drug Target Review) The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.
news Soluble fibrinogen a potential target for neurodegeneration 9 November 2021 | By Anna Begley (Drug Target Review) In a pre-clinical study, fibrinogen increased the death of mouse brain neurons, suggeting fibrin can have similar toxic effects on neurons.
news ABI3 gene may be the key to new Alzheimer’s disease therapies 8 November 2021 | By Anna Begley (Drug Target Review) The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
news Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction 4 November 2021 | By Anna Begley (Drug Target Review) ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
news Gene therapy bolsters Parkinson’s drug benefits in pre-clinical study 3 November 2021 | By Anna Begley (Drug Target Review) The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
news Scientists eliminate key Alzheimer’s feature in animal model 1 November 2021 | By Anna Begley (Drug Target Review) Turning off NHE6 in mice in pre-clinical studies prevented amyloid beta aggregation, a key feature of Alzheimer's disease, pointing to new therapies.
news $9 million grant awarded to uncover whether Parkinson’s starts in the nose 29 October 2021 | By Anna Begley (Drug Target Review) A new grant will allow an international team to determine if scent-processing nerves in the nose play a role in the development of Parkinson's and could aid in the development of novel therapeutics.
news Gene therapy shows promise for Angelman syndrome treatment 26 October 2021 | By Anna Begley (Drug Target Review) A new gene therapy restored motor skill-learning and usual behaviours in Angelman syndrome mouse models, suggesting a novel therapy for the condition.
news Scientists identify protein that prevents HSV-1 brain damage 20 October 2021 | By Anna Begley (Drug Target Review) Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
news Measuring microRNAs in blood may indicate dementia risk 14 October 2021 | By Anna Begley (Drug Target Review) Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
news Mission Therapeutics receives $500k grant for Parkinson’s research 14 October 2021 | By Anna Begley (Drug Target Review) Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.
news Neurolysin shown to be potential drug target for ischemic stroke 13 October 2021 | By Anna Begley (Drug Target Review) Researchers are identifying molecules that interact with neurolysin, a peptidase that helps protect the brain against stroke.
news Discovery unveils genetic risk factor shared by Alzheimer’s and COVID-19 12 October 2021 | By Anna Begley (Drug Target Review) Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
news Stealth BioTherapeutics reports positive pre-clinical data for ALS candidate 11 October 2021 | By Anna Begley (Drug Target Review) Stealth BioTherapeutic's SBT-272 improved mitochondrial motility in a murine model of amyotrophic lateral sclerosis.
news Chemotherapy drug reverses Alzheimer’s symptoms in mice 7 October 2021 | By Anna Begley (Drug Target Review) Axitinib, a common chemotherapy drug, restored memory and cognitive function in mouse models, representing a potential Alzheimer’s treatment.
